

Cytochrome P450-mediated metabolic engineering: current progress and future challenges[☆]

Hugues Renault^{1,2}, Jean-Etienne Bassard³, Björn Hamberger³ and Danièle Werck-Reichhart^{1,2,4}

Cytochromes P450 catalyze a broad range of regiospecific, stereospecific and irreversible steps in the biosynthetic routes of plant natural metabolites with important applications in pharmaceutical, cosmetic, fragrance and flavour, or polymer industries. They are consequently essential drivers for the engineered bioproduction of such compounds. Two ground-breaking developments of commercial products driven by the engineering of P450s are the antimalarial drug precursor artemisinic acid and blue roses or carnations. Tedious optimizations were required to generate marketable products. Hurdles encountered in P450 engineering and their potential solutions are summarized here. Together with recent technical developments and novel approaches to metabolic engineering, the lessons from this pioneering work should considerably boost exploitation of the amazing P450 toolkit emerging from accelerated sequencing of plant genomes.

Addresses

¹ Institute of Plant Molecular Biology of CNRS UPR2357, University of Strasbourg, F-67084 Strasbourg, France

² Freiburg Institute for Advanced Studies (FRIAS), University of Freiburg, Germany

³ Department of Plant and Environmental Sciences, Faculty of Science, University of Copenhagen, Thorvaldsensvej 40, 1871 Copenhagen, Denmark

⁴ University of Strasbourg Institute for Advanced Study (USIAS), France

Corresponding author: Werck-Reichhart, Danièle (werck@unistra.fr)

Current Opinion in Plant Biology 2014, **19**:27–34

This review comes from a themed issue on **Physiology and metabolism**

Edited by **Sarah O'Connor** and **Tom Brutnell**

1369-5266/\$ – see front matter, © 2014 The Authors. Published by Elsevier Ltd. All rights reserved.

<http://dx.doi.org/10.1016/j.pbi.2014.03.004>

Introduction

Cytochromes P450 (P450s) constitute the most extensively studied class of enzymes with more than 69 000 articles published at the end of 2013 (<http://www.ncbi.nlm.nih.gov/queried/20/12/2013> with 'P450' or 'P-450') according to PubMed count. An initial strong interest was fostered by

the essential roles of several P450s in mammalian drug metabolism with wide-ranging implications in medicine and pharmacology [1]. It now appears that they also form by far the largest superfamily of enzymes, essentially due to the expansion of the enzyme family in plants. As of December 2013, the count of annotated plant P450s, not including allelic variants, is 7512 (David Nelson, personal communication). It is expected that this number will increase in parallel with the exponential increase in sequencing information resulting from ongoing large-scale plant genome/transcriptome sequencing efforts (e.g. www.onekp.com). This rapidly expanding repository of P450 sequences could hold the key to bioengineering and emerging synthetic biology, when developed into an amazing functional toolkit.

It has been estimated that plants produce more than 200 000 metabolites as signalling, allelochemicals or defence compounds, to interact with and adapt to their environment. These metabolites have the potential to provide a major source of new drugs and bioactive compounds for cosmetics and biopesticides [2,3]. Cytochromes P450 catalyze most of the rate-limiting (with turnovers rates typically in the ten to a few hundreds per minute range) and completely irreversible reactions in their biosynthetic pathways, usually regio-specific and stereospecific oxygenations or oxidations, but also more complex reactions such as dealkylation, deamination, decarboxylation, C–C cleavage, ring expansion, ring opening, ring migration, ring coupling and dehydration [4,5].

Extraction of most bioactive compounds from plants is achieved with low yield in a costly, season-dependent and time consuming manner, and is therefore not sustainable. Moreover, many plants containing pharmaceutically interesting compounds are not cultivable, or are at risk of extinction in their natural habitat. Chemical synthesis of complex plant metabolites is excessively expensive. Metabolic engineering in microbial or plant hosts offers a more cost-effective alternative for production of compounds marketable as 'natural' products. We summarize here recent advances involving a combination of gene function discovery and complex metabolic engineering that demonstrate how P450s can be exploited for drug production or to confer valuable traits to plants for various applications. We also discuss specific limitations and pitfalls associated with this class of enzymes, as well as new trends and technical advances expected to significantly speed-up P450 exploitation in biotechnology.

[☆] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Potential applications for P450s in metabolic engineering

P450s contribute to the biosynthesis and/or catabolism of all phytohormones, and of many biopolymer (e.g. lignin, cutin, suberin, sporopollenin) subunits, pigments, fragrances, flavours, antioxidants, allelochemicals and defence compounds, among which are many compounds of commercial interest. Oxidations are critical steps for the cross-linking of biopolymers and for the formation of bioactive compounds, and are most often a prerequisite for further decorations or modifications essential for bioactivity. For example, 97% of the 46 000 current recorded plant terpenoids (one of the major classes of bioactive compounds: Dictionary of Natural Products (<http://dnp.chemnetbase.com>) accessed February, 2014; DNP 22.2 Taylor & Francis Group) are oxygenated [6,7]. When displaying relaxed substrate specificity, P450s can also participate to the activation or catabolism of xenobiotics, such as industrial pollutants or pesticides [8]. Herbicide detoxifying plant P450s can be exploited as selectable markers for plant transformation [9], whereas bacterial or human P450 enzymes have been expressed in plants for the purpose of bioremediation and the removal of pollutants, including explosives or pesticides [10,11,12]. Conversely, suppression of herbicide (nicosulfuron) detoxification in corn was recently developed as a tool for controlling the spread of transgenes [13]. So far, only a very small part of the huge potential provided by plant P450s has been exploited. A few examples will be illustrated below.

Major achievements: from engineered production of artemisinic acid to flower colour modification


Numerous P450s are already present in the metabolic engineering toolbox with 2880 US issued patents related to the use of P450s (source: www.google.com/patents; query: 'cytochrome P450' + 'metabolic engineering'), of which around 25% are associated with plants (query: 'cytochrome P450' + 'metabolic engineering' + 'plant'). Few of those, however, have led to commercial applications.

The most prominent story in synthetic biology for drug production was recently reported by Paddon and co-workers [14]. Artemisinin, a sesquiterpenoid originally sourced from *Artemisia annua*, is used in combination therapy for malaria. A stable supply of inexpensive artemisinin is essential in the developing world, where Malaria is a leading cause for death and disease. The effort for process development was thus supported by the Bill & Melinda Gates foundation. It was initially found that a single P450 expressed in the trichomes of *A. annua*, CYP71AV1, catalyzes the three successive oxidations steps leading from amorpha-4,11-diene to artemisinic acid [15,16]. CYP71AV1 was thus a prime target for engineered semisynthetic production of artemisinin

(Figure 1a). Commercially relevant yield (25 g/L) was achieved in baker's yeast after multiple steps of optimization [14]. The first steps led to optimized production of amorphaadiene in yeast via expression of the amorphaadiene synthase from *A. annua*, but also up regulation and fine-tuning of all enzymes of the mevalonate pathway and down regulation of *ERG9* (encoding squalene synthase and involved in biosynthesis of sterols) which competes with the introduced pathway [17,18]. The next stage required optimization of electron transfer to CYP71AV1, via moderate expression of the NADPH dependent P450 oxidoreductase (POR) and introduction of *A. annua* cytochrome *b₅*, preventing the observed formation of reactive oxygen and the accumulation of toxic intermediates that interfered with yeast viability. The third stage utilized acceleration of the formation and channelling of final oxidation products by co-expression of an artemisinic aldehyde dehydrogenase and an alcohol dehydrogenase, both highly represented in *A. annua* trichome ESTs (Figure 1a). Final improvements were obtained via optimized yeast cultivation and extractive fermentation processes [14]. This outstanding work provides a thorough and instructive example of metabolic engineering whose lessons will undoubtedly help speed up future engineering attempts. It also reveals that although some oxidation cascades can be achieved by P450s alone, additional oxidoreductases can be critical to drive fluxes compatible with viable pathways.

Long and sustained efforts were also required to bring to the market flowers with modified colours using CYP75 enzymes [19], which are the only CYP-engineered plants marketed so far. Anthocyanidins determine the colour of flowers, which shifts from orange via red to violet and blue hues with increasing hydroxyl groups on the B-ring. This hydroxylation pattern is determined by two P450 enzymes of the CYP75 family: the flavonoid 3'- and 3',5'-hydroxylase (Figure 1b: CYP75B and CYP75A, respectively). The corresponding genes were initially identified in petunia and have subsequently been identified and isolated from a range of different plants [19]. The top-selling cut-flowers such as rose, carnation or chrysanthemum never show blue shades in nature due to a CYP75A deficiency. Whereas plant engineering towards blue flowers seemed initially straightforward, complex and often empirical strategies had to be implemented to obtain marketable products. In addition to overexpression of a CYP75A gene, these strategies included promoter optimization (e.g. promoter from a snapdragon chalcone synthase), selection of suitable genetic background, including silencing of competing pathways, and choice of most efficient CYP75A gene (with pansy CYP75A showing highest efficiency owing to better mRNA stability). Further colour improvements were achieved via coexpression of a 4-dihydroflavanol reductase (DFR) with appropriate substrate specificity, and of the flavone synthase II CYP93B, yet another

Figure 1



Cytochrome P450 functions in the engineered artemisinin and anthocyanin pathways. **(a)** Cytochrome P450-catalyzed reactions in the artemisinin pathway: hydroxylation of amorpha-4,11-diene to produce artemisinic alcohol (1) is catalyzed by the cytochrome P450 CYP71AV1. Artemisinic alcohol is then synergistically oxidized (2) by CYP71AV1 and ADH1 (artemisinic alcohol dehydrogenase 1) to produce artemisinic aldehyde, which is also synergistically converted into artemisinic acid (3) by CYP71AV1 and ALDH1 (artemisinic aldehyde dehydrogenase 1). Optimal CYP71AV1 activity requires two electron donors POR (P450:oxidoreductase) and Cyt b_5 (cytochrome b_5). **(b)** Structure and colour of the main types of flower anthocyanidins. Members of the CYP75B subfamily are flavonoid 3'-hydroxylases (F3'H), catalyzing B-ring 3'-hydroxylation to produce cyanidin-derived red/magenta pigments. Members of the CYP75A subfamily are flavonoid 3',5'-hydroxylases (F3'5'H), catalyzing both B-ring 3'-hydroxylation and 5'-hydroxylation leading to delphinidin-derived violet/blue pigments. Plants deficient in both CYP75A and CYP75B proteins accumulate pelargonidin-derived red/orange pigments.

flavonoid hydroxylase, leading to a deepening and increase of the blue colour through formation of co-pigments [19^{••}]. Other parameters such as vacuolar pH and metal ion content required control. Optimal electron transfer was found to be important in some carnation varieties, requiring overexpression of cytochrome b_5 for accumulation of the blue pigment delphinidin. This is most likely related to the previously reported requirement of cytochrome b_5 for CYP75A, but not for CYP75B activity in petunia [20]. A similar strategy with further promoter enhancement recently led to the generation of violet/blue chrysanthemums [21].

Conversely, efforts for engineering pink flowers from native blue cultivars via suppression of CYP75B and CYP75A and overexpression of a heterologous *DFR* gene from geranium led to pink torenia flowers [22], whereas


CYP75A suppression was sufficient to shift cyclamen flowers to orange-red [23].

Both these success stories illustrate that engineering of industrially relevant processes or products requires more than P450 expression in a heterologous organism. Optimization of both metabolic fluxes and electron transfer is required.

The challenge of electron source and transfer

Oxygen activation by P450s requires two electrons (for an update on P450 mechanism see [24]), which are provided *in vivo* via different donor proteins or short protein cascades [25]. Those depend on organism and subcellular compartment. While diversified electron donor systems have evolved in microorganisms, plant P450 enzymes normally require a POR as minimal electron donor, and

Figure 2



Main natural and engineered sources of electrons exploited for P450-driven reactions. In a natural context, the two electrons required for P450 reactions are most often transferred from an N-terminally membrane-anchored P450:oxidoreductase (POR) (a); natural or artificial soluble P450-POR proteins fusions (as shown in (d)) can be found or generated. In some instances, a C-terminally membrane anchored cytochrome b₅ (Cyt b₅) is required to provide the second electron, Cyt b₅ being itself reduced by a cytochrome b₅ reductase (b₅R) (b). Recent work demonstrates that it is possible to use photosystem I (PSI)-derived electrons to reduce P450 enzymes via ferredoxin (Fd) *in vitro* and *in vivo* (c). Electrode-driven reduction of soluble P450 is possible *in vitro*, especially when fused to a redox partner (d).

both P450 and POR co-localize on the membrane of endoplasmic reticulum (or in a few cases on the plastid envelope) anchored via their N-terminus (Figure 2a). Achieving high plant P450 activity in microbial cells usually requires co-expression of a plant POR [26,27]. However, cytochrome b₅ might favour (or even be required for) reduction of some P450 enzymes (Figure 2b) [14^{••},19^{••},28]. Excess expression of POR is toxic for the cells since it leads to electron transfer uncoupling and the generation of chemically generated reactive oxygen species (see e.g. [14^{••},29]). Probably for this reason, P450s are usually found in large excess to POR in plant or animal cells. Optimization of electron flux to P450s is thus an important aspect of process development. Some microorganisms have solved this problem by evolving highly catalytically efficient soluble P450-POR fusion proteins, the most famous example of which is P450_{BM3} from *Bacillus megaterium*. Artificial P450-POR fusions were generated with some success in *Escherichia coli* where POR and ER membranes are absent. For example the CYP725A4 from Pacific yew,

which catalyses the first oxidation step in the biosynthesis of the anticancer compound paclitaxel, was found to be active in *E. coli* as a fusion with yew POR [30]. Likewise, plant P450s have been fused to the bacterial POR domain from *Rhodococcus*, generating active enzymes [31]. However, the arbitrary linkage and protein interactions in such artificial constructs is not optimized by evolution, and could therefore lead to poorly performing enzymes, uncoupling of electron transfer and other deleterious cellular effects. Optimization of electron transfer via directed saturation mutagenesis of the electron donor interface of a bacterial enzyme has been recently reported [32].

The fact that ferredoxins mediate electron transfer in mitochondrial and some bacterial P450 systems, and also function as electron carriers in the photosynthetic chain, has inspired attempts to replace NADPH by a light-generated source of electrons in P450 catalyzed biosynthesis of natural products (Figure 2c). Isolated photosystem I membrane complexes in combination with ferredoxin as an electron carrier were shown to support

P450 based mono-oxygenations *in vitro*, supporting the concept of engineering light-driven biosynthesis in synthetic biology [33]. The same team delivered demonstration for an entire biosynthetic pathway elegantly in an *in vivo* system, effectively rerouting photosynthetic reducing equivalents into production of a bioactive natural compound [34**]. The key to their strategy was to exploit the highly compartmentalized nature of plant pathways, breaking the separation of photosynthetic energy generation in chloroplasts and P450 based biosynthetic routes localized to the endoplasmic reticulum. This was achieved by re-targeting three enzymes to the chloroplast. These were two P450s and one glycosyl-transferase, constituting the entire biosynthetic pathway of the plant defence compound dhurrin, a cyanogenic glucoside found in *Sorghum bicolor*. It was demonstrated that reduced ferredoxin generated by photosystem I provided the electrons for the P450 reactions directly, effectively circumventing involvement of NADPH and the POR [34**]. Alternative approaches aiming at bypassing NADPH dependence such as coupling of the P450 with photosensitisers to generate the electrons [35], or non-enzymatic NADPH regeneration with artificial electron donors and mediators [36] are in their infancy and have so far only been tested with the soluble bacterial P450_{BM3} and complex polypyridin-ruthenium compounds. While interesting from a technological perspective, the practical and economic feasibility, and transferability to true production systems of these technologies remain to be demonstrated.

Pitfalls of P450-driven metabolic engineering and potential solutions

P450-mediated metabolic engineering is usually not a straightforward process. The main challenges and their possible solutions are summarized in Table 1. The main limitation for pathway reconstruction in microorganisms is quite often the level of expression of P450 enzymes. About 40% of plant P450s are poorly expressed, if at all, in yeast (from a sample of more than 250 from different plant species: author's lab statistics). For enzyme functional characterization, expression in insect cells or plant tissues can provide alternate strategies, which are not necessarily relevant for industrial production. Recoding to match yeast codon usage is not often helpful, although partial recoding [37] or reducing RNA structure might provide a more useful approach [38]. A common problem encountered with heterologously produced bioactive products is their inherent toxicity when accumulated as aglycones. In particular, isoprenoid oxygenated products resulting from P450-mediated decoration are usually more toxic than the corresponding olefins and exert this toxicity via accumulation in cellular membranes as has been recently shown for nootkatol [39]. In addition, alcohol intermediates may inhibit P450-catalyzed reactions via direct coordination to the heme iron in the active site [39]. Plants provide excellent core metabolism platforms to graft specialized pathways, but also present a major challenge because of their propensity for further conversion of the desired activated

Table 1

Pitfalls, challenges of P450 engineering and possible solutions

	References
Expression level/protein stability and activity	
Codon optimization	[38,41]
Secondary structure optimization	[38]
Decrease expression of POR	[14**]
Co-express other POR	[26,27,42]
Use other more stable ortholog	[19**,28]
Change expression system	[14**,52]
Expensive co-factors	
Whole-cell biotransformation	[14**,18,39,53*]
Co-factor regenerating system	[36,54,55]
Light-driven electron transfer	[33,34**,56]
Electrode-driven electron transfer	[57–59]
Toxicity of substrate/intermediates/product	
Biphasic bioreactor	[14**,41]
Anion-exchange products trapping	[60]
Conjugation of products	[39,61]
Compartmentation of products	[50,51]
Boost flux to final non-toxic products	[14**,30]
Lack of specificity/efficiency/alternative enzyme	
Screen natural enzyme collections	[39,46,47,59]
Directed evolution	[62]
Active site design	[45**,63,64]
Metabolic flux control	
Host engineering: expression of upstream/supporting enzymes or silencing of side-branch pathways	[14**,17,18,28,30,41,42]
Use of more appropriate natural genetic background	[14**,28]
Co-express optimal protein sets/modular pathway reconstitution/Expression level control	[14**,21,28,30,42,65]

products into conjugates or other derivatives due to the activity of the host plant enzymes (see e.g. [40]). Via insertion of hydroxyl groups on hydrophobic hydrocarbon structures, P450s provide grips to oxidoreductases and conjugations enzymes present in the host organism. Fast channelling of activated metabolic intermediates to downstream products is thus required.

New targets and future developments

The main targets for P450-mediated engineered production are high-value metabolites with applications in fragrance/flavour, cosmetics or pharmaceutical industries. With the development of next generation sequencing, those are now low-hanging fruits. There are recent reports of partial reconstruction of pathways for the production of the diterpenoid taxol [30], triterpenoid ginsenosides [41] and norditerpenoids tashinones [42], all for pharmaceutical applications. The natural pathways will be exploited, but the availability of large gene collections also pave the way for combinatorial assembly of non-natural enzyme sequences for generation of novel compounds by a synthetic biology approach [43,44], thus expanding the already huge repertoire of plant metabolites. Moreover, natural enzyme structures will be redesigned to permit non-natural reactions as recently elegantly illustrated by the replacement of the heme axial cysteine ligand with a serine in the bacterial P450_{BM3} which generated a C–C bond forming enzyme catalyzing olefin cyclopropanation [45••].

Beside tapping the immense resource for natural enzymes, major innovations are expected from technical developments such as novel nanoscale high-throughput functional screening systems [46,47], enzyme trapping and stabilization in membrane substitutes such as lipid nanodiscs [48] or amphipols [49]. The use of new convenient plant hosts amenable to homologous recombination and easily grown in controlled environment, such as algae or moss, or of specialized plant cell types providing suitable metabolic backgrounds and allowing product compartmentation to alleviate toxicity, such as trichomes [50,51], will open new avenues for plant supported production of valuable compounds.

Acknowledgements

H.R. and D.W. are grateful to the Agence Nationale de la Recherche for the funding of the ANR-10-BLAN-1528 PHENOWALL project, and to the University of Strasbourg Institute for Advanced Study (USIAS) and the Freiburg Institute for Advanced Studies (FRIAS) for the funding of the METABEVO project. D.W. in addition acknowledges the support of the European Community's Framework VII Program FP7/2007-2013 to the SMARTCELL project KBBE-2007-3-1-01. B.R.H. and J.-E.B. wish to acknowledge financial support provided by the UNIK [Universitätsforschungsprojekte Investitionskapital (Investment Capital for University Research)] Center for Synthetic Biology 'bioSYNergy', funded by the Research Initiative of the Danish Ministry of Science, Technology and Innovation. Authors also thank the PlantEngine (COST Action FA1006) for networking support and D.P. Drew for critical reading and editing of the manuscript.

References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Nebert DW, Wikvall K, Miller WL: **Human cytochromes P450 in health and disease**. *Philos Trans R Soc Lond B: Biol Sci* 2013, **368**:20120431.
2. Newman DJ, Cragg GM: **Natural products as sources of new drugs over the 30 years from 1981 to 2010**. *J Nat Prod* 2012, **75**:311-335.
3. Rischer H, Hakkinen ST, Ritala A, Seppanen-Laakso T, Miralpeix B, Capell T, Christou P, Oksman-Caldentey KM: **Plant cells as pharmaceutical factories**. *Curr Pharm Des* 2013, **19**:5640-5660.
4. Bak S, Beisson F, Bishop G, Hamberger B, Hofer R, Paquette S, Werck-Reichhart D: **Cytochromes P450**. *Arabidopsis Book* 2011, **9**:e0144.
5. Guengerich FP, Isin EM: **Unusual cytochrome P450 enzymes and reactions**. In *Handbook of Metabolic Pathways of Xenobiotics*, vol 1. Edited by Lee P, Aizawa H, Gan L, Prakash C, Zhong D. John Wiley and Sons; 2014.
6. Hamberger B, Bak S: **Plant P450s as versatile drivers for evolution of species-specific chemical diversity**. *Philos Trans R Soc Lond B: Biol Sci* 2013, **368**:20120426.
7. Kumar S: **Engineering cytochrome P450 biocatalysts for biotechnology, medicine and bioremediation**. *Expert Opin Drug Metab Toxicol* 2010, **6**:115-131.
8. Powles SB, Yu Q: **Evolution in action: plants resistant to herbicides**. *Annu Rev Plant Biol* 2010, **61**:317-347.
9. Didierjean L, Gondet L, Perkins R, Lau SM, Schaller H, O'Keefe DP, Werck-Reichhart D: **Engineering herbicide metabolism in tobacco and Arabidopsis with CYP76B1, a cytochrome P450 enzyme from Jerusalem artichoke**. *Plant Physiol* 2002, **130**:179-189.
10. Rylott EL, Jackson RG, Sabbadin F, Seth-Smith HM, Edwards J, Chong CS, Strand SE, Grogan G, Bruce NC: **The explosive-degrading cytochrome P450 XplA: biochemistry, structural features and prospects for bioremediation**. *Biochim Biophys Acta* 2011, **1814**:230-236.
- An interesting overview on the unusual bacterial P450-flavodoxin fusion protein that degrades environmentally hazardous chemicals under both aerobic and anaerobic conditions.
11. Zhang Y, Liu J, Zhou Y, Gong T, Wang J, Ge Y: **Enhanced phytoremediation of mixed heavy metal (mercury)-organic pollutants (trichloroethylene) with transgenic alfalfa co-expressing glutathione S-transferase and human P450 2E1**. *J Hazard Mater* 2013, **260**:1100-1107.
12. Shimazu S, Inui H, Ohkawa H: **Phytomonitoring and phytoremediation of agrochemicals and related compounds based on recombinant cytochrome P450s and aryl hydrocarbon receptors (AhRs)**. *J Agric Food Chem* 2011, **59**:2870-2875.
13. Li J, Yu H, Zhang F, Lin C, Gao J, Fang J, Ding X, Shen Z, Xu X: **A built-in strategy to mitigate transgene spreading from genetically modified corn**. *PLOS ONE* 2013, **8**:e81645.
- An interesting novel approach using silencing of a natural herbicide detoxification gene in maize as a tool to control dissemination of genetically modified crops.
14. Paddon CJ, Westfall PJ, Pitera DJ, Benjamin K, Fisher K, McPhee D, Leavell MD, Tai A, Main A, Eng D et al.: **High-level semi-synthetic production of the potent antimalarial artemisinin**. *Nature* 2013, **496**:528-532.
- The outcome of a seven-year struggle to develop an effective and economically sustainable process for the engineered production of the antimalarial drug precursor artemisinic acid. This paper provides an illustration of step-by-step improvements required for viable drug production based on a relatively simple and short pathway.
15. Teoh KH, Polichuk DR, Reed DW, Nowak G, Covello PS: **Artemisia annua L. (Asteraceae) trichome-specific cDNAs**

- reveal CYP71AV1, a cytochrome P450 with a key role in the biosynthesis of the antimalarial sesquiterpene lactone artemisinin. *FEBS Lett* 2006, **580**:1411-1416.
16. Ro DK, Paradise EM, Ouellet M, Fisher KJ, Newman KL, Ndungu JM, Ho KA, Eachus RA, Ham TS, Kirby J et al.: **Production of the antimalarial drug precursor artemisinic acid in engineered yeast.** *Nature* 2006, **440**:940-943.
 17. Westfall PJ, Pitera DJ, Lenihan JR, Eng D, Woolard FX, Regentin R, Horning T, Tsuruta H, Melis DJ, Owens A et al.: **Production of amoradiene in yeast, and its conversion to dihydroartemisinic acid, precursor to the antimalarial agent artemisinin.** *Proc Natl Acad Sci U S A* 2012, **109**:E111-E118.
 18. Keasling JD: **Synthetic biology and the development of tools for metabolic engineering.** *Metab Eng* 2012, **14**:189-195.
 19. Tanaka Y, Brugliera F: **Flower colour and cytochromes P450.** • *Philos Trans R Soc Lond B: Biol Sci* 2013, **368**:20120432.
A comprehensive review summarizing the different tools and optimizations that were required to engineer anthocyanidin colour shift in flowers of different plant species. It shows how different requirements are in various species and genetic backgrounds, and that different P450 genes encoding enzymes with the same activity can differentially impact flower coloration when expressed in plant.
 20. de Vetten N, ter Horst J, van Schaik HP, de Boer A, Mol J, Koes R: **A cytochrome b5 is required for full activity of flavonoid 3',5'-hydroxylase, a cytochrome P450 involved in the formation of blue flower colors.** *Proc Natl Acad Sci U S A* 1999, **96**:778-783.
 21. Noda N, Aida R, Kishimoto S, Ishiguro K, Fukuchi-Mizutani M, Tanaka Y, Ohmiya A: **Genetic engineering of novel bluer-colored chrysanthemums produced by accumulation of delphinidin-based anthocyanins.** *Plant Cell Physiol* 2013, **54**:1684-1695.
 22. Nakamura N, Fukuchi-Mizutani M, Fukui Y, Ishiguro K, Suzuki K, Suzuki H, Okazaki K, Shibata D, Tanaka Y: **Generation of pink flower varieties from blue *Torenia hybrida* by redirecting the flavonoid biosynthetic pathway from delphinidin to pelargonidin.** *Plant Biotechnol* 2010, **27**:375-383.
 23. Boase MR, Lewis DH, Davies KM, Marshall GB, Patel D, Schwinn KE, Derolles SC: **Isolation and antisense suppression of flavonoid 3',5'-hydroxylase modifies flower pigments and colour in cyclamen.** *BMC Plant Biol* 2010, **10**:107.
 24. Munro AW, Girvan HM, Mason AE, Dunford AJ, McLean KJ: **What makes a P450 tick?** *Trends Biochem Sci* 2013, **38**:140-150.
 25. Guengerich FP, Munro AW: **Unusual cytochrome P450 enzymes and reactions.** *J Biol Chem* 2013, **288**:17065-17073.
 26. Park S, Kim YS, Rupasinghe SG, Schuler MA, Back K: **Rice P450 reductases differentially affect P450-mediated metabolism in bacterial expression systems.** *Bioprocess Biosyst Eng* 2013, **36**:325-331.
 27. Neunzig I, Widjaja M, Peters FT, Maurer HH, Hehn A, Bourgaud F, Bureik M: **Coexpression of CPR from various origins enhances biotransformation activity of human CYPs in *S. pombe*.** *Appl Biochem Biotechnol* 2013, **170**:1751-1766.
 28. Brugliera F, Tao GQ, Tems U, Kalc G, Mouradova E, Price K, Stevenson K, Nakamura N, Stacey I, Katsumoto Y et al.: **Violet/blue chrysanthemums—metabolic engineering of the anthocyanin biosynthetic pathway results in novel petal colors.** *Plant Cell Physiol* 2013, **54**:1696-1710.
 29. Bassard JE, Mutterer J, Duval F, Werck-Reichhart D: **A novel method for monitoring the localization of cytochromes P450 and other endoplasmic reticulum membrane associated proteins: a tool for investigating the formation of metabolons.** *FEBS J* 2012, **279**:1576-1583.
 30. Ajikumar PK, Xiao WH, Tyo KE, Wang Y, Simeon F, Leonard E, Mucha O, Phon TH, Pfeifer B, Stephanopoulos G: **Isoprenoid pathway optimization for Taxol precursor overproduction in *Escherichia coli*.** *Science* 2010, **330**:70-74.
 31. Schuckel J, Rylott EL, Grogan G, Bruce NC: **A gene-fusion approach to enabling plant cytochromes p450 for biocatalysis.** *ChemBiochem* 2012, **13**:2758-2763.
 32. Ba L, Li P, Zhang H, Duan Y, Lin Z: **Semi-rational engineering of cytochrome P450sca-2 in a hybrid system for enhanced catalytic activity: insights into the important role of electron transfer.** *Biotechnol Bioeng* 2013, **110**:2815-2825.
 33. Jensen K, Johnston JB, de Montellano PR, Moller BL: **Photosystem I from plants as a bacterial cytochrome P450 surrogate electron donor: terminal hydroxylation of branched hydrocarbon chains.** *Biotechnol Lett* 2012, **34**:239-245.
 34. Nielsen AZ, Ziersen B, Jensen K, Lassen LM, Olsen CE, Moller BL, • Jensen PE: **Redirecting photosynthetic reducing power toward bioactive natural product synthesis.** *ACS Synth Biol* 2013, **2**:308-315.
This proof-of-concept study highlights the potential of controlling the subcellular localisation of P450 based pathways. Formation of bioactive natural compounds in plastids was demonstrated, the cellular compartment where carbon building blocks, energy and reduction power are abundant and, at least to some degree dispensable.
 35. Tran NH, Nguyen D, Dwaraknath S, Mahadevan S, Chavez G, Nguyen A, Dao T, Mullen S, Nguyen TA, Cheruzel LE: **An efficient light-driven P450 BM3 biocatalyst.** *J Am Chem Soc* 2013, **135**:14484-14487.
 36. Lee SH, Kwon YC, Kim DM, Park CB: **Cytochrome P450-catalyzed O-dealkylation coupled with photochemical NADPH regeneration.** *Biotechnol Bioeng* 2013, **110**:383-390.
 37. Norholm MH, Toddo S, Virkki MT, Light S, von Heijne G, Daley DO: **Improved production of membrane proteins in *Escherichia coli* by selective codon substitutions.** *FEBS Lett* 2013, **587**:2352-2358.
 38. Goodman DB, Church GM, Kosuri S: **Causes and effects of N-terminal codon bias in bacterial genes.** *Science* 2013, **342**:475-479.
 39. Gavira C, Hofer R, Lesot A, Lambert F, Zucca J, Werck-Reichhart D: **Challenges and pitfalls of P450-dependent (+)-valencene bioconversion by *Saccharomyces cerevisiae*.** *Metab Eng* 2013, **18**:25-35.
 40. Höfer R, Dong L, Andre F, Ginglinger JF, Lugan R, Gavira C, Grec S, Lang G, Memelink J, Van Der Krol S et al.: **Geraniol hydroxylase and hydroxygeraniol oxidase activities of the CYP76 family of cytochrome P450 enzymes and potential for engineering the early steps of the (seco)iridoid pathway.** *Metab Eng* 2013, **20C**:221-232.
 41. Dai Z, Liu Y, Zhang X, Shi M, Wang B, Wang D, Huang L, Zhang X: **Metabolic engineering of *Saccharomyces cerevisiae* for production of ginsenosides.** *Metab Eng* 2013, **20**:146-156.
 42. Guo J, Zhou YJ, Hillwig ML, Shen Y, Yang L, Wang Y, Zhang X, Liu W, Peters RJ, Chen X et al.: **CYP76AH1 catalyzes turnover of miltiradiene in tanshinones biosynthesis and enables heterologous production of ferruginol in yeasts.** *Proc Natl Acad Sci U S A* 2013, **110**:12108-12113.
 43. Fukushima EO, Seki H, Sawai S, Suzuki M, Ohyama K, Saito K, • Muranaka T: **Combinatorial biosynthesis of legume natural and rare triterpenoids in engineered yeast.** *Plant Cell Physiol* 2013, **54**:740-749.
A proof-of-concept paper for synthetic biology showing that it is possible to create new-to-nature compounds via combinatorial expression of triterpenoid biosynthetic enzymes.
 44. Moses T, Pollier J, Thevelein JM, Goossens A: **Bioengineering of plant (tri)terpenoids: from metabolic engineering of plants to synthetic biology in vivo and in vitro.** *New Phytol* 2013, **200**:27-43.
 45. Coelho PS, Wang ZJ, Ener ME, Baril SA, Kannan A, Arnold FH, • Brustad EM: **A serine-substituted P450 catalyzes highly efficient carbene transfer to olefins in vivo.** *Nat Chem Biol* 2013, **9**:485-487.
A very innovative approach showing that it is possible to modify a canonic feature of the P450 enzymes such as the heme ligand to generate an enzyme with different catalytic activity.
 46. Wollenberg LA, Jett JE, Wu Y, Flora DR, Wu N, Tracy TS, Gannett PM: **Selective filling of nanowells in nanowell arrays fabricated using polystyrene nanosphere lithography with cytochrome P450 enzymes.** *Nanotechnology* 2012, **23**:385101.

47. Wollenberg LA, Kabulski JL, Powell MJ, Chen J, Flora DR, Tracy TS, Gannett PM: **The use of immobilized cytochrome P450C9 in PMMA-based plug flow bioreactors for the production of drug metabolites.** *Appl Biochem Biotechnol* 2013;1-14.
48. Bayburt TH, Sligar SG: **Membrane protein assembly into nanodiscs.** *FEBS Lett* 2010, **584**:1721-1727.
49. Laursen T, Naur P, Moller BL: **Amphipol trapping of a functional CYP system.** *Biotechnol Appl Biochem* 2013, **60**:119-127.
50. Tissier A: **Glandular trichomes: what comes after expressed sequence tags?** *Plant J* 2012, **70**:51-68.
51. Lange BM, Turner GW: **Terpenoid biosynthesis in trichomes—current status and future opportunities.** *Plant Biotechnol J* 2013, **11**:2-22.
52. Ginglinger JF, Boachon B, Hofer R, Paetz C, Kollner TG, Miesch L, Lugan R, Baltenweck R, Mutterer J, Ullmann P *et al.*: **Gene coexpression analysis reveals complex metabolism of the monoterpene alcohol linalool in arabidopsis flowers.** *Plant Cell* 2013.
53. Nguyen TD, MacNevin G, Ro DK: **De novo synthesis of high-value plant sesquiterpenoids in yeast.** *Methods Enzymol* 2012, **517**:261-278.
- An excellent comprehensive walk-through for yeast engineering for production of oxygenated sesquiterpenoids.
54. Siriphongphaew A, Pisnupong P, Wongkongkatap J, Inprakhon P, Vangnai AS, Honda K, Ohtake H, Kato J, Ogawa J, Shimizu S *et al.*: **Development of a whole-cell biocatalyst co-expressing P450 monooxygenase and glucose dehydrogenase for synthesis of epoxyhexane.** *Appl Microbiol Biotechnol* 2012, **95**:357-367.
55. Janocha S, Bernhardt R: **Design and characterization of an efficient CYP105A1-based whole-cell biocatalyst for the conversion of resin acid diterpenoids in permeabilized *Escherichia coli*.** *Appl Microbiol Biotechnol* 2013, **97**:7639-7649.
56. Jensen K, Jensen PE, Moller BL: **Light-driven cytochrome P450 hydroxylations.** *ACS Chem Biol* 2011, **6**:533-539.
57. van der Felt C, Hindoyan K, Choi K, Javdan N, Goldman P, Bustos R, Star AG, Hunter BM, Hill MG, Nersissian A *et al.*: **Electron-transfer rates govern product distribution in electrochemically-driven P450-catalyzed dioxygen reduction.** *J Inorg Biochem* 2011, **105**:1350-1353.
58. Sadeghi SJ, Fantuzzi A, Gilardi G: **Breakthrough in P450 bioelectrochemistry and future perspectives.** *Biochim Biophys Acta* 2011, **1814**:237-248.
59. Schneider E, Clark DS: **Cytochrome P450 (CYP) enzymes and the development of CYP biosensors.** *Biosens Bioelectron* 2013, **39**:1-13.
60. Alonso-Gutierrez J, Chan R, Bath TS, Adams PD, Keasling JD, Petzold CJ, Lee TS: **Metabolic engineering of *Escherichia coli* for limonene and perillyl alcohol production.** *Metab Eng* 2013, **19**:33-41.
61. Tattersall DB, Bak S, Jones PR, Olsen CE, Nielsen JK, Hansen ML, Hoj PB, Moller BL: **Resistance to an herbivore through engineered cyanogenic glucoside synthesis.** *Science* 2001, **293**:1826-1828.
62. Jung ST, Lauchli R, Arnold FH: **Cytochrome P450: taming a wild type enzyme.** *Curr Opin Biotechnol* 2011, **22**:809-817.
63. McIntosh JA, Coelho PS, Farwell CC, Wang ZJ, Lewis JC, Brown TR, Arnold FH: **Enantioselective intramolecular C-H amination catalyzed by engineered cytochrome P450 enzymes in vitro and in vivo.** *Angew Chem Int Ed Engl* 2013, **52**:9309-9312.
64. Dietrich JA, Yoshikuni Y, Fisher KJ, Woolard FX, Ockey D, McPhee DJ, Renninger NS, Chang MC, Baker D, Keasling JD: **A novel semi-biosynthetic route for artemisinin production using engineered substrate-promiscuous P450(BM3).** *ACS Chem Biol* 2009, **4**:261-267.
65. Koopman F, Beekwilder J, Crimi B, van Houwelingen A, Hall RD, Bosch D, van Maris AJ, Pronk JT, Daran JM: **De novo production of the flavonoid naringenin in engineered *Saccharomyces cerevisiae*.** *Microb Cell Fact* 2012, **11**:155.